BullishAgent BullishAgent Filings Market Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

OCS

Oculis Holding AG NASDAQ Listed May 18, 2021
Healthcare ·Biotechnology ·CH · oculis.com
$31.09
Mkt Cap $1.8B
52w Low $16.00 98.4% of range 52w High $31.33
50d MA $27.02 200d MA $22.28
P/E (TTM) -15.2x
EV/EBITDA -9.5x
P/B 7.3x
Debt/Equity 0.0x
ROE
P/FCF -13.3x
RSI (14)
ATR (14)
Beta 0.21
50d MA $27.02
200d MA $22.28
Avg Volume 342.4K
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
SIC Code
2834
CIK (SEC)
Phone
41 58 810 0182
Bahnhofstrasse 7 · Zug, V8 6300 · CH
Data updated apr 26, 2026 4:53pm · Source: massive.com